Online inquiry

IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4746MR)

This product GTTS-WQ4746MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Osteogenesis imperfecta (OI) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4746MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8977MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ4015MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ1346MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ12590MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ4790MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ7892MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ7155MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ15462MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW